<DOC>
	<DOCNO>NCT00482833</DOCNO>
	<brief_summary>Open label , randomise , phase III multicenter trial .</brief_summary>
	<brief_title>Phase III Trial Acute Promyelocytic Leukemia Patients</brief_title>
	<detailed_description>- Arm I : - Induction therapy : Patients receive oral tretinoin twice daily arsenic trioxide IV 2 hour day 1-60 . Patients achieve hematological complete remission go receive consolidation therapy . - Consolidation therapy : Patients receive oral tretinoin twice daily day 1-14 . Treatment tretinoin repeat every 4 week 7 course . Patients also receive arsenic trioxide IV 2 hour day 1-5 week 1-4 . Treatment arsenic trioxide repeat every 8 week 4 course . - Arm II : - Induction therapy : Patients receive tretinoin arm I induction therapy idarubicin IV 20 minute day 2 , 4 , 6 , 8 . Patients achieve hematological complete remission go receive consolidation therapy . - Consolidation therapy : Patients receive oral tretinoin twice daily day 1-45 , idarubicin IV 20 minute day 1-4 day 31 , mitoxantrone hydrochloride IV 30 minute day 16-20 . Marrow sample collect completion consolidation therapy analyze reverse transcriptase-PCR molecular remission . Patients achieve molecular remission ( PML-RARa negative ) go receive maintenance therapy . - Maintenance therapy : Patients receive oral mercaptopurine daily methotrexate intramuscularly weekly 3 month . Treatment mercaptopurine methotrexate repeat every 3 month 7 course . After completion course 1 mercaptopurine methotrexate , patient receive oral tretinoin daily day 1-15* . Treatment tretinoin repeat every 3 month 6 course . NOTE : *Patients receive mercaptopurine methotrexate tretinoin administration . After completion study therapy , patient follow periodically 5 year . As 14th September 2010 , patient need evaluate primary endpoint ( 162 patient ) recruit trial accrual continue order ass one secondary outcome ( QoL ) . ''</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Inclusion criterion Signed write informed consent accord IGH/EU/GCP national local law Newly diagnose APL cytomorphology , confirm also molecular analysis* . Age ≤18 &lt; 71 year WHO performance status 0 2 include WBC diagnosis ≤ 10 x 109/L Serum total bilirubin ≤ 3.0 mg/dL ( ≤ 51µmol/L ) Serum creatinine ≤ 3.0 mg/dL ( ≤ 260 µmol/L ) The confirmation diagnosis genetic level ( microspeckled PML nuclear distribution PGM3 monoclonal antibody and/or PML/RARa fusion RTPCR and/or demonstration ( 15 ; 17 ) karyotyping ) mandatory patient eligibility . However , order avoid delay treatment initiation , patient randomise basis morphologic diagnosis result genetic test available . Exclusion criterion Age &lt; 18 ≥ 71 WBC diagnosis &gt; 10 x 109/L Other active malignancy time study entry Lack diagnostic confirmation genetic level Significant arrhythmia , EKG abnormality ( *see ) neuropathy Other cardiac contraindication intensive chemotherapy ( LVEF &lt; 50 % ) Uncontrolled , lifethreatening infection Severe noncontrolled pulmonary cardiac disease Women either pregnant breast feeding , childbearing potential , defined woman physiologically capable become pregnant , UNLESS meet one follow definition : Amenorrhea ; post surgical bilateral oophorectomy without hysterectomy ; use highly effective method birth control ( define result failure rate le 1 % per year ) use consistently correctly implant , injectables , oral contraceptive , IUDs , sexual abstinence vasectomize partner . Concomitant severe psychiatric disorder HIV positivity *EKG abnormality : Congenital long QT syndrome ; History presence significant ventricular atrial tachyarrhythmia Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec screen EKG ( use QTcF formula detail page 18 ) Right bundle branch block plus leave anterior hemiblock , bifascicular block Use investigational drug time enrolment within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>